BX-471 Berlex.
Berlex and its parent company, Schering AG, are developing BX-471 (also known as ZK-811752), the lead in a series of non-peptide chemokine receptor 1 (CCR1) antagonists, for the potential treatment of autoimmune diseases, in particular multiple sclerosis (MS) [291682], [376290], [411184]. In March 2000, BX-471 was undergoing phase I trials for the potential treatment of autoimmune diseases [362022]; phase I trials in MS were ongoing in March 2002 [441989], [443941]. Positive results from these trials have been reported and Berlex was planning phase II trials in MS patients as of mid-March 2002 [444906]. In July 2001, Schering estimated filing in the US and EU in 2008 [411184], [416493]. WO-09856771 claims piperazinyl derivatives, pharmaceutical compositions comprising them and their use in the treatment of inflammatory conditions.
Elices
Mariano J
MJ
camarel@earthlink.net
D000818:Animals; D001327:Autoimmune Diseases / Q000188:drug therapy; D017321:Clinical Trials, Phase I as Topic; D004353:Drug Evaluation, Preclinical; D006084:Graft Rejection / Q000188:drug therapy; D006801:Humans; D009103:Multiple Sclerosis / Q000188:drug therapy*; D010671:Phenylurea Compounds / Q000737:chemistry / Q000627:therapeutic use*; D010880:Piperidines / Q000737:chemistry / Q000627:therapeutic use*; D054389:Receptors, CCR1; D019707:Receptors, Chemokine / Q000037:antagonists & inhibitors*; D013329:Structure-Activity Relationship; D016896:Treatment Outcome
C515300:CCR1 protein, human; D010671:Phenylurea Compounds; D010880:Piperidines; D054389:Receptors, CCR1; D019707:Receptors, Chemokine; C411885:BX 471